Bispecific antibodies and uses thereof

Recombinant bispecific antibodies targeting CD16a and IL-21 molecules on NK cells activate and enhance their antitumor and antiviral functions, addressing the limitations of existing NK cell activation methods in the tumor microenvironment.

JP2024541005AActive Publication Date: 2024-11-06SHANGHAI NK CELLTECH CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024524501
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-20
Filing Date
2022-08-24
Publication Date
2024-11-06
Estimated Expiration
2042-08-24

AI Technical Summary

Technical Problem

Current methods to restore the antitumor and antiviral functions of NK cells in the tumor microenvironment are limited, as they do not effectively activate NK cells to overcome immunosuppression and enhance their cytotoxic activity.

Method used

Development of recombinant bispecific antibodies combining CD16a and IL-21 molecules to specifically bind to NK cells, triggering activation cascades and enhancing IFN-γ secretion, proliferation, and cytotoxic activity.

Benefits of technology

The recombinant antibodies effectively activate NK cells, restoring their function in the tumor microenvironment, enhancing antitumor and antiviral capabilities, and promoting NK cell maturation and receptor expression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541005000003
    Figure 2024541005000003
  • Figure 2024541005000004
    Figure 2024541005000004
  • Figure 2024541005000005
    Figure 2024541005000005
Patent Text Reader

Abstract

The present invention provides a bispecific antibody and its use, the bispecific antibody comprising an IL-21 molecule, a CD16a single chain antibody and Fc, the N-terminus of the Fc being connected to the C-terminus of the single chain antibody, the CD16a single chain antibody comprising a CD16a antibody comprising a heavy chain variable region and a light chain variable region, the C-terminus of the Fc being connected to the N-terminus of the IL21 molecule. The prepared bispecific antibody can simultaneously target CD16 and IL-21 receptors to activate NK cells, has a long half-life, and exhibits stronger anti-tumor and anti-virus abilities than single target antibodies, while promoting the proliferation of NK cells and potentially being applied to culture and expand NK cells in vitro, and the expanded NK cells have good cytotoxicity.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the biopharmaceutical field, in particular to bispecific antibodies and uses thereof, and more particularly to recombinant antibodies, immune cells, nucleic acids, expression vectors, recombinant cells, compositions, the use of said substances in drug production, and reagent kits. [Background technology]

[0002] Bispecific antibodies are antibodies that can specifically bind two antigen sites at the same time. NK cells are the main effector cells of the innate immune system. Compared with T cells, NK cells do not require prior stimulation, and can kill tumor cells and virus-infected cells without MHC restriction by using perforin and granule enzymes and related mechanisms. NK cells express a large number of activating receptors, and can effectively identify stress ligands produced by tumor cells or infected cells, thereby effectively killing tumor cells. At the same time, tumor cells also secrete and produce a large number of immunosuppressive molecules, forming an immunosuppressive tumor microenvironment, suppressing the activity and anti-tumor ability of NK cells in this environment, and causing NK cells to become exhausted. At present, there are also many methods to restore the exhaustion of NK cells in the tumor microenvironment, such as immune test point blocking, activating antibodies, and activating cytokines, which can provide activating signals to NK cells, block inhibitory signals in the tumor microenvironment, restore NK cells to a normal activation state, and allow them to exert anti-tumor or anti-viral functions.

[0003] CD16a is an important activating receptor expressed on NK cells. When CD16a is activated by its ligand or antibody binding, it induces various cascade activation reactions and releases granule enzymes, perforin, inflammatory cytokines and chemokines, which gives NK cells a strong activation effect and enhanced antitumor ability. IL-21R (IL-21 receptor) is a cytokine receptor constitutively expressed on NK cells. When it is recognized, bound and activated by its corresponding ligand IL-21 molecule, for mouse NK cells, this process promotes the increase of these NK cell particles, enhances the expression of perforin, increases the secretion of IFN-γ and promotes the effector activity; for human NK cells, this process enhances the secretion of IFN-γ, improves the proliferation and cytotoxic activity of NK, and at the same time accelerates the maturation of NK cells and the expression of NK cell receptors. Therefore, the development of highly targeted bispecific antibodies is of great value in the prevention and treatment of tumors. Summary of the Invention [Problem to be solved by the invention]

[0004] This application was made based on the inventor's discovery and realization of the following facts and problems.

[0005] In the present invention, the inventors combine CD16a antibody and IL-21 molecule to design a recombinant bispecific antibody, which can specifically bind to CD16a and IL-21 receptor (IL-21R), and further targeting IL-21 molecule and CD16a antibody to be close to NK cells and bind to CD16a and / or IL-21R on NK cells, thereby inducing various cascade activation reactions, activating NK cells, and recovering the exhaustion of NK cells in the tumor microenvironment, while enhancing IFN-γ secretion, improving the proliferation and cytotoxic activity of NK, and at the same time, accelerating the maturation of NK cells and the expression of NK cell receptors to kill tumor cells or virus-infected cells, and the recombinant bispecific antibody has high CD16a and IL-21R binding activity, and has strong anti-tumor and anti-virus capabilities. [Means for solving the problem]

[0006] Therefore, in a first aspect of the present invention, the present invention provides a recombinant antibody. According to an embodiment of the present invention, the recombinant antibody comprises an IL-21 molecule and a CD16a antibody, the CD16a antibody comprises a CD16a single chain antibody and an Fc region, the N-terminus of the Fc region is connected to the C-terminus of the single chain antibody, the CD16a single chain antibody comprises a heavy chain variable region and a light chain variable region, and the C-terminus of the Fc is connected to the N-terminus of the IL21 molecule. The recombinant antibody according to an embodiment of the present invention can effectively bind to CD16a and IL-21R, has strong in vivo and exogenous binding activity, can effectively activate NK cells, has a long in vivo half-life, and has significant antitumor and antiviral effects.

[0007] In a second aspect of the present invention, the present invention provides a nucleic acid, which according to an embodiment of the present invention encodes a recombinant antibody according to the first aspect. The recombinant antibody encoded by the nucleic acid according to the embodiment of the present invention can effectively bind to CD16a and IL-21R, has strong in vivo and exogenous binding activity, can effectively activate NK cells, has a long half-life in vivo, and has significant antitumor and antiviral effects.

[0008] In a third aspect of the present invention, the present invention provides an expression vector. According to an embodiment of the present invention, the expression vector carries the nucleic acid according to the second aspect. The expression vector may comprise a selectable control sequence, which is operably connected to the nucleic acid molecule. The control sequence is one or more control sequences capable of directing the expression of the nucleic acid molecule in a host. The expression vector proposed in the embodiment of the present invention can efficiently express the recombinant antibody in a suitable host cell and further effectively activate NK cells, and is used for treating or preventing diseases caused by tumors or viral infections.

[0009] In a fourth aspect of the present invention, there is provided a recombinant cell. According to an embodiment of the present invention, the recombinant cell carries the nucleic acid molecule according to the second aspect, the expression vector according to the third aspect, or the recombinant antibody according to the first aspect. The recombinant cell is obtained by transfection or transformation of the expression vector. According to an embodiment of the present invention, the recombinant cell can efficiently express the recombinant antibody under appropriate conditions, and the recombinant cell can be effectively used for treating or preventing diseases caused by tumors or viral infections, and can effectively activate NK cells.

[0010] In a fifth aspect of the present invention, a composition is provided, which according to an embodiment of the present invention comprises the recombinant antibody according to the first aspect, the nucleic acid molecule according to the second aspect, the expression vector according to the third aspect, or the recombinant cell according to the fourth aspect. As described above, the recombinant antibody according to the embodiment of the present invention can effectively bind to CD16a and IL-21R protein molecules, and further specifically recognizes NK cells highly expressing the IL-21R and / or CD16a, and effectively activates the NK cells. The composition comprising the recombinant antibody also plays a significant role in treating or preventing diseases caused by tumors or viral infections, and has significant antitumor and antiviral abilities.

[0011] In a sixth aspect of the present invention, the present invention provides a use of the recombinant antibody according to the first aspect, the nucleic acid molecule according to the second aspect, the expression vector according to the third aspect, the recombinant cell according to the fourth aspect or the composition according to the fifth aspect in the manufacture of a medicament. According to an embodiment of the present invention, the medicament is used for treating or preventing tumor or viral infection. As described above, the recombinant antibody according to an embodiment of the present invention can effectively bind to CD16a and IL-21R protein molecules, and further specifically recognizes NK cells highly expressing the IL-21R and / or CD16a, and the medicament manufactured using the recombinant antibody and its corresponding series of substances also plays a significant role in the treatment or prevention of tumor or viral infection, and has significant antitumor and antiviral abilities.

[0012] In a seventh aspect of the present invention, there is provided a use of the recombinant antibody according to the first aspect, the nucleic acid molecule according to the second aspect, the expression vector according to the third aspect and the recombinant cell according to the fourth aspect in culturing and expanding NK cells. The recombinant antibody, the nucleic acid molecule, the expression vector and the recombinant cell according to embodiments of the present invention can be used to promote the proliferation and expansion of the NK cells in vitro, and the expanded NK cells have good cytotoxicity.

[0013] In the eighth aspect of the present invention, a drug is provided. According to an embodiment of the present invention, the drug includes the recombinant antibody according to the first aspect, the nucleic acid molecule according to the second aspect, the expression vector according to the third aspect, the recombinant cell according to the fourth aspect, or the composition according to the fifth aspect, and is used for treating or preventing tumors or viral infections. As described above, the recombinant antibody according to the embodiment of the present invention can effectively bind to CD16a and IL-21R protein, and can specifically recognize NK cells highly expressing IL-21R and / or CD16a. The drug prepared using the recombinant antibody and a series of corresponding substances also plays a significant role in treating or preventing tumors or viral infections, and has significant antitumor and antiviral abilities.

[0014] In a ninth aspect of the present invention, a reagent kit is provided, which according to an embodiment of the present invention comprises the recombinant antibody according to the first aspect. The recombinant antibody according to the embodiment of the present invention can effectively bind to CD16a and IL-21R protein molecules, and can specifically recognize NK cells that specifically and highly express IL-21R or CD16a. Therefore, the recombinant antibody can be used to prepare a reagent kit for detecting CD16a and / or IL-21R, and the reagent kit can be used in scientific research, such as qualitatively or quantitatively detecting CD16a and / or IL-21R protein molecules in biological samples to obtain biological samples that meet requirements.

[0015] In the tenth aspect of the present invention, the present invention provides the use of the above-mentioned recombinant antibody, nucleic acid molecule, expression vector, recombinant cell, composition or drug in treating or preventing tumor or viral infection. As described above, the recombinant antibody can specifically recognize the above-mentioned CD16a and IL-21R protein, and can specifically recognize NK cells that specifically and highly express the IL-21R or CD16a, effectively activating NK cells, enhancing IFN-γ secretion, improving proliferation and NK cytotoxic activity, effectively killing tumor cells, and at the same time, accelerating the maturation of NK cells and the expression of NK cell receptors, and relieving the depletion of NK cells in tumor microenvironment. Therefore, the recombinant antibody according to the embodiment of the present invention, the composition containing the recombinant antibody, the drug or a series of substances that can be expressed under suitable conditions to obtain the recombinant antibody, such as the above-mentioned nucleic acid molecule, expression vector, recombinant cell, etc., can effectively activate NK cells and further treat or prevent tumor or viral infection.

[0016] In an eleventh aspect of the present invention, the present invention provides a method for treating or preventing a tumor or a viral infection, which, according to some specific embodiments of the present invention, comprises administering to a subject at least one of 1) the recombinant antibody described above, 2) the nucleic acid molecule described above, 3) the expression vector described above, 4) the recombinant cell described above, 5) the composition described above, or 6) the drug described above. As described above, the recombinant antibody can specifically recognize the above CD16a and IL-21R proteins, and further, can specifically recognize NK cells that specifically and highly express the IL-21R or CD16a, effectively activating NK cells, enhancing IFN-γ secretion, improving the proliferation and NK cytotoxic activity, effectively killing tumor cells, and at the same time, accelerating the maturation of NK cells and the expression of NK cell receptors, and relieving the depletion of NK cells in the tumor microenvironment. Therefore, the recombinant antibody according to the embodiments of the present invention, a composition comprising the recombinant antibody, a drug, or a series of substances that can be expressed under appropriate conditions to obtain the recombinant antibody, such as the above nucleic acid molecules, expression vectors, recombinant cells, etc., can all effectively activate NK cells, and further treat or prevent tumors or viral infections.

[0017] Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. [Brief description of the drawings]

[0018] The above and / or additional aspects and advantages of the present invention will become apparent and will be readily understood from the following detailed description of the embodiments taken in conjunction with the drawings. [Figure 1] FIG. 1 is a schematic diagram showing a bispecific antibody expression vector according to an embodiment of the present invention. [Diagram 2] FIG. 2 is a structural diagram showing a recombinant bispecific antibody according to an embodiment of the present invention, in which Linker1 represents connecting peptide 1, Linker2 represents connecting peptide 2, Anti-CD16A represents a CD16A single-chain antibody, and Hinge represents the hinge region. [Diagram 3]FIG. 3 shows the analysis results of recombinant bispecific antibody anti-CD16A-FCγ4-IL21 expression clone screening according to an embodiment of the present invention, in which FIG. A(3-A) shows the DB, Dot blot, and dot hybridization detection results, and FIG. B(3-B) shows the WB: Western blot, immunoblot (anti-human FCγ4 antibody) detection results. [Figure 4] FIG. 4 shows the analytical results of the fermentation expression of recombinant bispecific antibody anti-CD16A-FCγ4-IL21 according to an embodiment of the present invention, in which FIG. A(4-A) shows the results of monitoring each parameter during the fermentation process, and FIG. B(4-B) shows the detection results at the time of accumulation of the target protein. [Diagram 5] 5 shows the results of purification and physicochemical identification of recombinant bispecific antibody anti-CD16A-FCγ4-IL21 according to an embodiment of the present invention, in which: FIG. A(5-A) is the protein purity SDS-PAGE detection result of anti-CD16A-FCγ4-IL21; FIG. B(5-B) is the dynamic light scattering detection result of anti-CD16A-FCγ4-IL21, in which the three solid lines represent three repetitions of the same treatment; and FIG. C(5-C) is the HPLC detection result of anti-CD16A-FCγ4-IL21. [Figure 6] FIG. 1 is a graph showing the results of detecting the activity of in vitro activated NK cells by the recombinant bispecific antibody anti-CD16A-FCγ4-IL21 according to an embodiment of the present invention, in which the abscissa indicates molecules whose expression changed on the surface of NK cells in PBMCs after activation by anti-CD16A-FCγ4-IL21, and the ordinate Positive rate of NK surface molecules (%) indicates the positive rate (expression status) of NK cell surface molecules. [Figure 7]FIG. 7-A is a graph showing the results of NK cell expansion by in vitro induction of the bispecific antibody molecule anti-CD16a-FCγ4-IL21 according to an embodiment of the present invention, and the expansion effect. FIG. 7-A shows the expansion of NK cells by in vitro induction of the bispecific antibody molecule anti-CD16a-FCγ4-IL21, where the abscissa (Day) indicates the number of days, and the ordinate (NK Percentage (%)) indicates the percentage of NK cells. FIG. 7-B is a graph showing the results of NK cell expansion by in vitro induction of the bispecific antibody molecule anti-CD16a-FCγ4-IL21, where the abscissa (Day) indicates the number of days, and the ordinate (Fold increase of NK cell number) indicates the expansion fold of NK cells in the expansion system. FIG. 7-C is a graph showing the results of NK cell expansion by in vitro induction of the bispecific antibody molecule anti-CD16a-FCγ4-IL21, where the abscissa (Day) indicates the number of days, and the ordinate (Fold increase of cell number) indicates the expansion fold of total cells in the expansion system. Figure D (7-D) shows the results of cell subclass analysis obtained after in vitro expansion of PBMC-derived NK cells with the bispecific antibody molecule anti-CD16a-FCγ4-IL21, where the abscissa indicates the cell subgroup classification and the ordinate Percentage (%) indicates the average cell percentage. Figure E (7-E) shows the results of detection of NK cell cytotoxicity by the expansion of the bispecific antibody molecule anti-CD16a-FCγ4-IL21, where the abscissa indicates the percentage of CD56 positive cells and K562 cells and the ordinate Specific killing (%) indicates the percentage of specific cells. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] Hereinafter, the embodiments of the present invention will be described in detail, and examples of the embodiments are shown in the drawings. The implementations described below with reference to the drawings are illustrative and are used only to interpret the present invention, and should not be understood as limitations on the present invention.

[0020] It should be noted that the terms "first", "second" and the like are for explanatory purposes only and cannot be considered to indicate or imply relative importance or to imply a number of technical features. Thus, a feature defined as "first" or "second" may expressly or imply that it includes one or more of the feature. In the present description, unless otherwise clearly and specifically limited, the concept of "plurality" is at least two, e.g., two or three.

[0021] Recombinant antibodies

[0022] In one aspect of the present invention, the present invention provides a recombinant antibody, comprising an IL-21 molecule and a CD16a antibody, the CD16a antibody comprising a CD16a single chain antibody and an Fc region, the N-terminus of the Fc region being linked to the C-terminus of the single chain antibody, the CD16a single chain antibody comprising a heavy chain variable region and a light chain variable region, and the C-terminus of the Fc being linked to the N-terminus of the IL21 molecule. The recombinant antibody according to the embodiment of the present invention can effectively bind to CD16a and IL-21R, has strong in vivo and exogenous binding activity, can effectively activate NK cells, has a long in vivo half-life, and has significant antitumor and antiviral effects.

[0023] According to some specific embodiments of the present invention, the above recombinant antibody may further include at least one of the following additional technical features:

[0024] According to some specific embodiments of the present invention, the antibody further comprises a connecting peptide 1, wherein the N-terminus of the connecting peptide 1 is connected to the C-terminus of the heavy chain variable region of the CD16a single chain antibody, and the C-terminus of the connecting peptide 1 is connected to the N-terminus of the light chain variable region of the CD16a single chain antibody.

[0025] According to some specific embodiments of the present invention, the connecting peptide 1 has the amino acid sequence shown in SEQ ID NO:1. GGGGSGGGGSGGGGS(SEQ ID NO: 1).

[0026] According to some specific embodiments of the present invention, the antibody further comprises a connecting peptide 2, wherein the N-terminus of the connecting peptide 2 is connected to the C-terminus of the IL-21 molecule, and the C-terminus of the connecting peptide 2 is connected to the N-terminus of the Fc region.

[0027] According to some specific embodiments of the present invention, the connecting peptide 2 has the amino acid sequence shown in SEQ ID NO:2. GGGGSGGGGSGGGGS(SEQ ID NO: 2).

[0028] According to some specific embodiments of the present invention, at least a portion of the Fc region is derived from at least one of a murine origin antibody, a human origin antibody, a primate origin antibody, or a variant thereof.

[0029] According to some specific embodiments of the invention, at least a portion of the Fc region is derived from a human source IgG or a variant thereof.

[0030] According to some specific embodiments of the present invention, at least a portion of the Fc region is derived from Fcγ4 or a variant thereof.

[0031] According to some specific embodiments of the invention, at least a portion of the Fc region is derived from a human source Fcγ4 or a variant thereof.

[0032] According to some specific embodiments of the present invention, the Fc region has the amino acid sequence shown in SEQ ID NO:3. APEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAK GQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO: 3).

[0033] According to some specific embodiments of the present invention, the recombinant antibody has the amino acid sequence shown in SEQ ID NO:4. (SEQ ID NO: 4).

[0034] Prophylactic or Therapeutic Compositions

[0035] In one aspect of the present invention, the present invention provides a nucleic acid, which encodes the recombinant antibody described above. The recombinant antibody encoded by the nucleic acid according to the embodiment of the present invention can effectively bind to CD16a and IL-21R, has strong in vivo and exogenous binding activity, can effectively activate NK cells, has a long half-life in vivo, and has significant antitumor and antiviral effects.

[0036] According to some specific embodiments of the invention, the nucleic acid has a nucleotide sequence as shown in SEQ ID NO:5.

[0037] It should be understood by those skilled in the art that the nucleic acids referred to in the present specification and claims actually include either or both of the complementary double strands. For convenience, in many cases, only one strand is shown in the specification and claims, but the other strand that is actually complementary to it is also disclosed. Also, the nucleic acid sequences in this application include DNA or RNA formats, and the disclosure of one means the disclosure of the other.

[0038] In another aspect of the present invention, the present invention provides an expression vector, which carries the nucleic acid molecule described above. The expression vector may include a selectable control sequence. The control sequence is operably connected to the nucleic acid molecule. The control sequence is one or more control sequences capable of directing the expression of the nucleic acid molecule in a host. The expression vector proposed in the embodiments of the present invention can efficiently express the recombinant antibody in a suitable host cell, and can also effectively activate NK cells, and is used for treating or preventing diseases caused by tumors or viral infections.

[0039] In another aspect of the present invention, a recombinant cell is provided, the recombinant cell carrying the above-mentioned nucleic acid molecule, expression vector or recombinant antibody. The recombinant cell is obtained by transfection or transformation with the above-mentioned expression vector. According to some specific embodiments of the present invention, the recombinant cell can efficiently express the above-mentioned recombinant antibody under appropriate conditions, and the recombinant cell can be effectively used for treating or preventing tumors or diseases caused by viral infection.

[0040] It should be noted that the "suitable conditions" referred to in the specification of the present application are conditions suitable for the expression of the recombinant antibody described in the present application. Those skilled in the art can easily understand that the conditions suitable for recombinant antibody expression include, but are not limited to, a suitable transformation or transfection method, suitable transformation or transfection conditions, healthy host cell state, suitable host cell density, suitable cell culture environment, and suitable cell culture time. The "suitable conditions" are not particularly limited, and those skilled in the art can optimize the optimal conditions for the expression of the recombinant antibody according to the specific environment of the laboratory.

[0041] In a further aspect of the present invention, the present invention provides a composition, comprising the recombinant antibody, nucleic acid molecule, expression vector or recombinant cell described above. As described above, the recombinant antibody according to the embodiment of the present invention can effectively bind to CD16a or IL-21R protein molecule, and can specifically recognize NK cells highly expressing IL-21R and / or CD16a, and can effectively activate NK cells. Similarly, a composition comprising the recombinant antibody plays a significant role in treating or preventing diseases caused by tumors or viral infections, and has significant antitumor and antiviral abilities. The composition is not particularly limited, and any of the above substances used in combination with any other substance, such as a food composition or a drug composition, is within the scope of the composition described in the present application.

[0042] In one aspect of the present invention, the present invention provides a drug, comprising the recombinant antibody nucleic acid molecule, expression vector, recombinant cell or composition described above, the drug being used for treating or preventing tumors or viral infections. As described above, the recombinant antibody according to the embodiment of the present invention can effectively bind to CD16a and IL-21R protein, and can specifically recognize NK cells highly expressing IL-21R and / or CD16a, and the drug prepared using the recombinant antibody and a series of corresponding substances also plays an important role in treating or preventing tumors or viral infections, and has significant antitumor and antiviral abilities.

[0043] According to some specific embodiments of the present invention, the tumor comprises at least one of colon cancer, lung cancer, breast cancer, liver cancer, gastric cancer, skin cancer, kidney cancer, pancreatic cancer and ovarian cancer.

[0044] According to some specific embodiments of the present invention, the viral infection comprises at least one of HPV, HBV, influenza virus, and coronavirus.

[0045] The drug according to some specific embodiments of the present invention comprises a pharma- ceutically acceptable vector and an effective amount of the recombinant antibody active ingredient.

[0046] As used herein, the term "effective amount" or "effective dosage" means an amount that is capable of producing a function or activity in humans and / or animals and that is acceptable to humans and / or animals.

[0047] As used herein, a "pharmaceutically acceptable" component is a substance that can be administered to humans and / or mammals without undue side effects (e.g., toxicity, irritation, and allergic reactions), i.e., with a reasonable benefit / risk ratio. The term "pharmaceutically acceptable vector" refers to a vector used to administer a therapeutic agent, including various excipients and diluents.

[0048] The drug of the present invention comprises a safe and effective amount of the active ingredient of the present invention and a pharma- ceutically acceptable vector. Such vectors include (but are not limited to) saline, buffer, glucose, water, glycerin, ethanol, and combinations thereof. In general, the drug formulation should be matched with the mode of administration, and the dosage form of the drug of the present invention is an injection, oral preparation (tablet, capsule, oral liquid), transdermal agent, sustained release agent. For example, it can be prepared by a conventional method using an aqueous solution containing physiological saline, glucose, and other auxiliary agents. It is preferable to prepare the above drug under aseptic conditions.

[0049] The effective amount of the active ingredient according to the present invention varies depending on the pattern of administration, the severity of the disease to be treated, etc. The selection of the preferred effective amount can be determined by those skilled in the art based on various factors (e.g., clinical trials). Such factors include, but are not limited to, the pharmacokinetic parameters of the active ingredient, such as bioavailability, metabolism, half-life, etc., the severity of the disease the patient is to be treated, the patient's body weight, the patient's immune status, the route of administration, etc. For example, depending on the exigencies of the treatment situation, separate doses can be administered several times a day, or the dose can be reduced proportionately.

[0050] Pharmaceutically acceptable vectors according to the present invention include, but are not limited to, water, saline, liposomes, lipids, proteins, protein-antibody complexes, peptide-based materials, cellulose, nanogels, or combinations thereof. The choice of vector should be matched with the mode of administration, which are well known to those skilled in the art.

[0051] use

[0052] In one aspect of the present invention, the present invention provides a use of the above-described recombinant antibodies, nucleic acid molecules, expression vectors and recombinant cells in the culture and expansion of NK cells. The recombinant antibodies, nucleic acid molecules, expression vectors and recombinant cells according to some specific embodiments of the present invention can be used to promote the proliferation and expansion of the NK cells in vitro, and the expanded NK cells have good cytotoxicity.

[0053] According to some specific embodiments of the present invention, the NK cells are derived from peripheral blood or obtained by inducing stem cells. NK cells are mainly distributed in peripheral blood, and the NK cells may be obtained by inducing stem cells.

[0054] According to some specific embodiments of the present invention, the NK cells include at least one of NK cells derived from human peripheral blood mononuclear cells, NK cells induced from human umbilical cord blood stem cells, NK cells induced from human embryonic stem cells, and NK cells induced from human iPSCs. NK cells peripheral blood mononuclear cells include lymphocytes and monocytes. According to some specific embodiments of the present invention, the recombinant antibody, nucleic acid molecule, expression vector, and recombinant cell in vitro described above can promote the proliferation of the derived NK cells, have good expansion effect, and the expanded NK cells have good cytotoxicity.

[0055] In the seventh aspect of the present invention, the present invention provides the use of the recombinant antibody, nucleic acid molecule, expression vector, recombinant cell or composition described above in a drug, which is used for treating or preventing tumor or viral infection. As described above, the recombinant antibody according to the embodiment of the present invention can effectively bind to CD16a and IL-21R protein molecules, and specifically recognizes NK cells highly expressing IL-21R and / or CD16a, and the drug prepared using the recombinant antibody and its corresponding series of substances also plays a significant role in treating or preventing tumor or viral infection, and has significant anti-tumor and anti-viral abilities.

[0056] According to some specific embodiments of the present invention, the above use may further include at least one of the following additional technical features:

[0057] According to some specific embodiments of the present invention, the tumor comprises at least one of colon cancer, lung cancer, breast cancer, liver cancer, gastric cancer, skin cancer, renal cancer, pancreatic cancer and ovarian cancer.

[0058] According to some specific embodiments of the present invention, the viral infection comprises at least one of HPV, HBV, influenza virus and coronavirus.

[0059] Reagent Kit

[0060] In a final aspect of the present invention, a reagent kit is provided, comprising the recombinant antibody described above. The recombinant antibody according to the embodiment of the present invention can effectively bind to CD16a and IL-21R protein molecules, and can specifically recognize NK cells that specifically and highly express IL-21R or CD16a. Therefore, the recombinant antibody can be used to prepare a reagent kit for detecting CD16a or IL-21R, which is used in scientific research, such as qualitatively or quantitatively detecting CD16a and / or IL-21R protein molecules in biological samples.

[0061] According to some specific embodiments of the present invention, the reagent kit is used for detecting CD16a and / or IL-21R.

[0062] Uses and methods for treating diseases

[0063] In one aspect of the present invention, the present invention provides the use of the above-mentioned recombinant antibody, nucleic acid molecule, expression vector, recombinant cell, composition or drug in treating or preventing tumor or viral infection. As described above, the recombinant antibody can specifically recognize the above-mentioned CD16a and IL-21R protein, and can specifically recognize NK cells that specifically and highly express IL-21R or CD16a, effectively activating NK cells, enhancing IFN-γ secretion, improving proliferation and NK cytotoxic activity, effectively killing tumor cells, and at the same time, accelerating NK cell maturation and NK cell receptor expression, and relieving the depletion of NK cells in tumor microenvironment. Therefore, the recombinant antibody according to the embodiment of the present invention, the composition containing the recombinant antibody, the drug or a series of substances that can be expressed under suitable conditions to obtain the recombinant antibody, such as the above-mentioned nucleic acid molecule, expression vector, recombinant cell, etc., can effectively activate NK cells and further treat or prevent tumor or viral infection.

[0064] According to some specific embodiments of the present invention, the tumor comprises at least one of rectal cancer, lung cancer, breast cancer, liver cancer, gastric cancer, skin cancer, renal cancer, pancreatic cancer and ovarian cancer.The viral infection comprises at least one of HPV, HBV, influenza virus and coronavirus.

[0065] In another aspect of the present invention, the present invention provides a method for treating or preventing tumors or viral infections. According to some specific embodiments of the present invention, the method includes administering to a subject at least one of the following: 1) the recombinant antibody described above; 2) the nucleic acid molecule described above; 3) the expression vector described above; 4) the recombinant cell described above; 5) the composition described above; or 6) the drug described above. As described above, the recombinant antibody can specifically recognize the above CD16a and IL-21R protein, and can specifically recognize NK cells that specifically and highly express IL-21R or CD16a, effectively activating NK cells, enhancing IFN-γ secretion, improving proliferation and NK cytotoxic activity, effectively killing tumor cells, and at the same time, accelerating the maturation of NK cells and the expression of NK cell receptors, and relieving the depletion of NK cells in tumor microenvironment. Therefore, the recombinant antibody according to the embodiments of the present invention, the composition containing the recombinant antibody, the drug, or a series of substances that can be expressed under appropriate conditions to obtain the recombinant antibody, such as the above nucleic acid molecule, expression vector, recombinant cell, etc., can effectively activate NK cells and further treat or prevent tumors or viral infections.

[0066] According to some specific embodiments of the present invention, the tumor comprises at least one of rectal cancer, lung cancer, breast cancer, liver cancer, gastric cancer, skin cancer, renal cancer, pancreatic cancer and ovarian cancer, and the viral infection comprises at least one of HPV, HBV, influenza virus and coronavirus.

[0067] The following examples are specifically described. If no specific techniques or conditions are shown in the examples, they should be carried out according to the techniques or conditions described in the literature in the field or according to the product specifications. If no manufacturer is shown for the reagents or equipment used, they are conventional products that can be purchased commercially.

[0068] Example 1 Design and construction of the bispecific antibody molecule anti-CD16a-FCγ4-IL21

[0069] The specific experimental procedure of this example is as follows. 1.1 Acquisition of anti-CD16a-FCγ4-IL21 fusion gene (1) Acquisition of Anti-CD16a-FCγ4 fusion gene Using the Pgapza-CD16-FC4γ4 plasmid as a template, PCR was performed using primer 1 and primer 2 to obtain the anti-CD16a-FCγ4 fusion gene, which has the nucleotide sequence shown in SEQ ID NO:6, with the PCR program: denaturation: 98°C, 20s; cycles: 98°C, 10s→54°C, 15s→72°C, 40s (30 cycles); extension: 72°C, 2min.

[0070] (2) Acquisition of the GS-IL21 fusion gene Using the picza-rdna-FC-Y407T-IL21 plasmid as a template, PCR was performed using primer 3 and primer 4 to obtain the GS-IL21 fusion gene, which has the nucleotide sequence shown in SEQ ID NO:7, with the PCR program: denaturation: 98°C, 20s; cycles: 98°C, 10s→54°C, 15s→72°C, 30s (30 cycles); extension: 72°C, 5min. GGTGGTGGTGGTTCTggaGGTggcGGTTCTGGTGGTGGTGGTTCTCAAGATCGCCACATGATTAGAATGCGTCAACTTATAGATATTGTTGATCAGCTGAAAAATTATGTGAATGACTTGGTCCCTGAATTTCTGCCAGCTCCAGAAGATGTAGAGACAAACTGTGAGTGGTCAGCTTTTTCCTGTTTTCAGAAGGCCCAACTAAAGTCAGCAAATACAGGA AACAATGAAAGGATAATCAATGTATCAATTAAAAAAGCTGAAGAGGAAACCACCTTCCACAAATGCAGGGAGAAGACAGAAACACAGACTAACATGCCCTTCATGTGATTCTTATGAGAAAAAACCACCCAAAGAATTCCTAGAAAGATTCAAATCACTTCTCCAAAAGATGATTCATCAGCATCTGTCCTCTAGAACACACGGAAGTGAAGATTCCTAG(SEQ ID NO:7).

[0071] The sequences of the primers 1-4 are shown in Table 1.

[0072] [Table 1]

[0073] The products after the above two-step amplification are subjected to agarose gel electrophoresis, and according to the operation steps of the DNA gel recovery reagent kit, the strips corresponding to the two target genes are cut and recovered to obtain the anti-CD16a-FCγ4 and GS-IL21 fusion genes, i.e., the first target gene fragment and the second target gene fragment.

[0074] (3) Acquisition of Anti-CD16a-FCγ4-IL21 fusion gene Use the Anti-CD16a-FCγ4 and GS-IL21 fusion genes obtained in the above steps as templates, and use primer 1 and primer 4 to perform PCR to obtain the Anti-CD16a-FCγ4-IL21 fusion gene. PCR program: denaturation: 98°C, 20s; 3 cycles: 98°C, 10s → 54°C, 20s → 72°C, 40s (3 cycles); extension: 72°C, 2min; then add primers: denaturation: 98°C, 20s; 3 cycles: 98°C, 10s → 54°C, 20s → 72°C, 40s (30 cycles); extension: 72°C, 10min; agarose gel electrophoresis is performed on the amplified product, and it is recovered with a DNA gel recovery reagent kit to obtain one segment of gene, which has XhoI and NotI enzyme cleavage sites at both ends and is named Anti-CD16a-FCγ4-IL21. The above-mentioned Pgapza-CD16-FC4γ4 and Ppicza-rdna-FC-Y407T-IL21 plasmids were both independently constructed by the inventors according to conventional methods for constructing expression vectors.

[0075] 1.2 Construction of Pichia coli expression vector for anti-CD16a-FCγ4-IL21 fusion protein The gene sequence of the coding anti-CD16a-FCγ4-IL21 fusion protein obtained in step 1.1 (SEQ ID NO:5) and the Pichia yeast expression plasmid PGAPzα-rDNA-NTS stored in the laboratory are subjected to double enzyme cleavage using restriction endonucleases Xhol and NotI. The enzyme-cleaved anti-CD16a-FCγ4-IL21 fusion protein gene sequence product gene is recovered with a PCR product recovery reagent kit (Axygen), and the enzyme-cleaved plasmid is recovered with a DNA gel recovery reagent kit (Axygen). Refer to the instructions for the reagent kit for the operation procedure. The enzyme-cleaved fusion protein gene and the enzyme-cleaved vector obtained by the recovery are ligated with T4 DNA ligase, and the plasmid structure after construction is shown in Figure 1. The enzyme ligation product is transformed into E. coli TOP10 receptor cells. The transformation procedure is as follows: 10 μL of the enzyme ligation product is added to 100 μL of E. coli receptor, mixed evenly, left on ice for 15-30 minutes, flicked evenly every 5 minutes, then heat stimulated at 42 ° C for 90 seconds, left on ice for 3-5 minutes, added 400 ul of antibiotic-free LB liquid medium, resuscitated at 37 ° C for 45 minutes on a rocking bed, and then applied to a Zeocin-resistant plate. After growing clonal bacterial colonies on the plate, a single colony clone is selected and placed in a cell culture tube containing LZ liquid medium (LB medium with Zeocin resistance) and cultured at 37 ° C for 6-8 h, and then PCR identification is performed using the bacterial liquid as a template, and the obtained positive clone is named PGAP-zα-anti-CD16a-FCγ4-IL21, and the bacterial liquid corresponding to the positive clone is extracted with a plasmid small amount extraction reagent kit and sent to a general-purpose organism for sequencing. After sequencing, the sequencing results are consistent with the theoretically expected results, and the clone construction is correct.

[0076] Example 2 Expression and purification of the bispecific antibody molecule anti-CD16a-FCγ4-IL21

[0077] 2.1 Expression of anti-CD16a-FCγ4-IL21 bispecific antibody molecule The positive clone constructed in Example 1 is expanded using 50 mL LZ liquid medium, and the plasmid PGAP-zα-anti-CD16a-FCγ4-IL21 is extracted using a medium-volume reagent kit (Axygen). The expression plasmid PGAP-zα-anti-CD16a-FCγ4-IL21 prepared in the previous step is linearized with endonuclease SpeI and recovered by ethanol precipitation. Ethanol precipitation step: 1) Add 2 volumes of absolute ethanol and 0.1 volumes of 3M sodium acetate to the enzyme cleavage reaction system, and precipitate at -20°C for more than 2 hours. 2) Centrifuge at 12000g for 10 minutes and discard the supernatant. 3) Resuspend and precipitate in 300 μL, 70% ethanol, centrifuge at 12000g for 10 minutes, and discard the supernatant. 4) Dry at 37°C, resuspend in deionized water, measure the concentration, and adjust the concentration to 0.5-1.0 μg / μL.

[0078] Preparation of yeast receptor: Preparation steps: 1) Take a well-frozen Bastepicia yeast X33 strain, draw a line on a YPD plate, and culture in a yeast culture tank at 30 ° C. 2) When the clone grows to about 1 mm in diameter, take the clone into liquid 4mLYPD medium, and culture the yeast in a rocking bed at 30 ° C. 3) Culture for 24-48 hours. Inoculate 1 mL of the bacterial solution into 50 mL of fresh YPD medium. 4) When the OD600 value reaches 1-1.5, transfer the bacterial solution to a 50 mL centrifuge tube, centrifuge at 1500 g for 5 minutes at 4 ° C., discard the supernatant. 5) Resuspend in 50 mL of ice water, centrifuge at 1500 g for 5 minutes at 4 ° C., discard the supernatant, and repeat once. 6) Resuspend in 50 mL of 1 M cold sorbitol, centrifuge at 1500 g for 5 min at 4°C, discard the supernatant, and repeat once. 7) Resuspend in 500 μL of 1 M cold sorbitol.

[0079] Electrotransformation step: 100μL of the above recipient cells are placed in a sterile pre-cooled electric rotation cup, 10μL of linearized plasmid (5-10μg) is added therein, and mixed evenly. Electric rotation meter parameters: set to 2000V, 200Ω, 25μF. After electric rotation, immediately add 1mL of 1M cold sorbitol to the electric rotation cup, and leave it on ice for 5-10min, then transfer the entire bacterial solution to a 50ml centrifuge tube containing 1ml of YPD, and revive it at 30℃, 225rpm for 2h. After the revival is completed, take 100-1000μL of the above bacterial solution and apply it to a YPDZ (Zeocin resistance-containing plate) plate, and place the plate in a constant temperature yeast culture tank at 30℃ for cultivation.

[0080] Positive expression clone screening: After growing the yeast clones on the YPDZ plates described above, select some clones into 2 mL of BMGY medium, and incubate the yeast on a rocking bed at 28° C. until the yeast liquid becomes milky white. 1mL of the resulting bacterial solution was frozen and stored to preserve the seeds. The remaining 1mL of the bacterial solution was centrifuged at 12000g for 5 minutes, and the supernatant was removed. An initial screening of Dot Blot identification was performed using anti-human Fcγ4 antibody to select yeast strains with relatively high expression levels. The yeast strains with relatively high expression levels were then spread onto a YPD plate containing zeocin, and several clones were selected from among them after the clones were grown. The bacteria were shaken as described above to obtain the bacterial supernatant. Western Blot identification analysis was performed using anti-human Fcγ antibody to screen for high-expression strains (34-3). The remaining 1mL of the corresponding strains was frozen and stored to preserve the seeds. This high-expression strain is a Pichia yeast strain that can express anti-CD16a-Fcγ4-IL21 complex protein.

[0081] The specific experimental results are shown in Figure 3. After screening the YPDZ-resistant culture plate, the yeast expression strain of the fusion protein is obtained. Initial screening is performed using dot blot to first obtain some clones with relatively high expression levels (numbers 66, 91, 98, and 34 in Figure 3B), which are then further confirmed and compared by Western blot to screen for yeast expression clones with high expression levels, which are then used for protein expression and purification.

[0082] 2.2 Fermentation, purification and identification of anti-CD16a-FCγ4-IL21 bispecific antibody molecule (1) Fermentation Expression strain culture: The recombinant strain is fermented according to the fermentation instruction manual of Invitrogen. The screened high expression strain is inoculated into a cell culture tube containing 4mL of YPD medium, and cultured on a rocking bed at 30℃ for 24-48 hours until the OD600 is 2-6, that is, the first-grade fermented seed liquid. 1mL of the seed liquid is transferred into a corn bottle containing 200mL of BMGY medium, and cultured on a rocking bed at 30℃ for 12-24 hours, that is, the second-grade fermented seed liquid. The entire 200mL of the second-grade seed liquid is inoculated into a fermentation tank containing 6L of BMGY medium. Parameter setting: monitor the culture temperature of 30℃, pH 7.0, dissolved oxygen, rotation speed, etc., and start the fermentation culture. In the bacterial growth stage, BMGY medium is used. When the dissolved oxygen increases rapidly, the basic glycerin in the medium is consumed, and glycerin is added at a rate of 90mL / h. The fermentation temperature is adjusted to 25℃, and the fermentation continues until completion.

[0083] Clarification of culture broth: After the fermentation is completed, centrifuge at 10,000g for 30 minutes, collect the supernatant, filter and clarify it through 0.22μm and 500kDa microfilters, and then adjust the pH to 7.4.

[0084] The monitoring of each parameter during the fermentation process is shown in Figure 4. The entire fermentation process lasted for 50 hours, and the fermentation process was stable and easy to repeat. As can be seen from Figure 4B, protein expression (20 h) was started by limited culture induction with the addition of glycerol from the end of the basal glycerol culture stage, and protein continued to accumulate throughout the entire process. There was no significant difference in the amount of protein accumulated from 43 to 50 h, which allowed us to determine the end point of fermentation.

[0085] (2) Refining Protein capture: The affinity column Mabselect is used to capture the recombinant fusion protein. The specific steps are: 1) Rinse the column with deionized water for 5 column volumes; 2) Rinse the column with PBS for 3 column volumes; 3) Load the sample; 4) After sample loading is finished, rinse the column with PBS for 3 column volumes; 5) Impurity wash: Rinse 5 column volumes with PH 5.5 citrate buffer; 6) Elute the target protein, and the eluate is PH 3.0 citrate buffer, which is used for subsequent purification after the collected eluate is concentrated.

[0086] Fine purification: Use AKTA PURE 25 to equilibrate Superdex200 molecular sieves with PBS buffer, after equilibration, add the sample to the neutral eluate, and collect the eluted sample after washing with PBS buffer to obtain anti-CD16a-FCγ4-IL21 recombinant protein. After two steps of purification, including centrifugal filtration, the protein purity reached 95% or more (Figure 5A, C) by SDS-PAGE and HPLC identification.

[0087] (3) Identification Recombinant protein identification: The purified protein was subjected to SDS-PAGE, HPLC and dynamic light scattering identification. The specific experimental results are shown in Figure 4B. The molecular weight of anti-CD16a-FCγ4-IL21 protein is about 135kDa, as expected. Dynamic light scattering identification showed that the molecular diameter of anti-CD16a-FCγ4-IL21 is about 10nm, with good intermolecular uniformity.

[0088] Example 3: Verification of in vitro NK cell activation function induced by bispecific antibody anti-CD16a-FCγ4-IL21

[0089] Human PBMCs were isolated using Ficoll density gradient centrifugation. The isolated PBMCs were diluted to 1.0 × 10 in RPMI 1640 containing 10% FBS. 6 Dilute the cells to 10 cells / mL. Add 10 mL of the diluted cells to a T25 culture bottle. After 12 hours of culture, add anti-CD16a-FCγ4-IL21 fusion protein to the culture bottle at a final concentration of 20 nM. After 24 hours of culture, detect the phenotypic changes of NK cells using a flow cytometer, mainly detecting the expression status of the main activating molecules CD69 and NKp44 on the surface of NK cells, and the killing molecules 4-1BB, TRAIL, and Granzyme B.

[0090] Specific experimental results are shown in Figure 6. In the control group (PBS) (compared to the control group) and the experimental group to which anti-CD16a-FCγ4-IL21 fusion protein was added, the expression levels of the main activating molecules CD69 and NKp44 on the surface of NK cells, as well as the killing molecules 4-1BB, TRAIL, and Granzyme B, were all significantly increased, indicating that NK cells were effectively activated by the anti-CD16a-FCγ4-IL21 fusion protein.

[0091] Example 4: Bispecific antibody molecule anti-CD16a-FCγ4-IL21 in vitro induced NK cell expansion and evaluation of expansion effect

[0092] 4.1 Detection of purity and number of anti-CD16a-FCγ4-IL21 amplified NK cells Coat T75 culture bottles with the fusion protein 24 h prior to incubation, taking 7.5 ml of coating solution per bottle to cover the bottom of the bottle body, and storing overnight in a 4°C refrigerator.

[0093] After isolating PBMC cells from blood samples, count (Millet counter) and record the percentage of each cell subpopulation in PBMC cells. Seed according to 1.5*10^6 / ml density (20ml culture volume). The total number of cells is 30*10^6. This is day 0. At the same time, add 1% IL2 (1000IU / ml) and 5% autologous plasma of the corresponding PBMC in KBM581 medium without anti-CD16a-FCγ4-IL21. On day 3, supplement with IL2 factor at 1% of the corresponding culture volume. On the fifth day, observe the color of the medium and the state of cell adhesion to the bottom of the T75 bottle body. If necessary, replenish with 5-10 mL of KBM581 medium containing anti-CD16a-FCγ4-IL21 and add IL2 (1000 IU / mL) factor at 1% of the supplementary liquid volume. On the 6th day, samples are taken and counted, and cell passage expansion culture (1.3*10^6 / mL) is performed. It is stained and labeled (CD16a / CD45 / CD56), and the percentage of the NK cell subpopulation and the percentage of the CD56+ cell subpopulation are detected by a flow cytometer, and the total cell number is calculated, and the number of NK cells is calculated from the flow purity detection results. After the 5th day, cell passage expansion culture is performed, and KBM581 medium containing anti-CD16a-FCγ4-IL21 is used, and 1% IL2 and 2% autologous plasma are added. On the seventh day, observe the color of the medium and the state of cell growth on the wall of the bottle, and replenish the medium as necessary (add IL2 factor at 1% by volume of the replenishment liquid). On day 8, sample and count. If necessary, passage expand cells (T75 or T175 bottles, 1.4*10^6 / ml) and supplement the medium with 1% IL2 factor, 2% autologous plasma. On the 9th day, observe the color of the medium and the state of cell growth on the wall of the bottle, and replenish the medium as necessary (add IL2 factor at 1% by volume of the replenishment liquid). On the 10th day, samples were taken and counted, and the cells were subcultured and expanded (1.5*10^6 / ml). They were stained (CD16a / CD45 / CD56) and the percentage of the NK cell subpopulation and the percentage of the CD56+ cell subpopulation were detected by a flow cytometer, and the total cell number was calculated, and the number of NK cells was calculated from the flow purity detection results. On the 12th day, observe the color of the medium and the state of cell growth on the wall of the bottle, and replenish the medium as necessary (add IL2 factor at 1% by volume of the replenishment liquid). On the 13th day, samples were taken and counted, and cell passage expansion culture (1.5*10^6 / mL) was performed. The cells were stained (CD16a / CD45 / CD56), and the percentage of the NK cell subpopulation and the percentage of the CD56+ cell subpopulation were detected by a flow cytometer. The total cell number was calculated, and the number of NK cells was calculated from the flow purity detection results. On day 15, sample and count. If necessary, perform cell passage expansion (T175 bolts or culture bags, 1.5*10^6 / mL) and add IL2 factor at 1% of the medium. On the 17th day, samples are taken and counted, and stained (CD16a / CD45 / CD56) is performed to detect the percentage of the NK cell subpopulation and the percentage of the CD56+ cell subpopulation by flow cytometer, and the total cell number is calculated, and the number of NK cells is calculated from the flow purity detection result. Graphs of the change in the proportion and number of NK cells over time are made according to the NK purity and cell number on days 0, 6, 10, 13, and 17.

[0094] Specific experimental results are shown in A to C of Figure 7. By amplifying NK cells derived from PBMC using anti-CD16a-FCγ4-IL21, the NK cells can be amplified, and the purity and amplification fold of NK cells can be improved, and the proportion of NK cells can reach the highest level of about 65% throughout the entire culture process.

[0095] 4.2 Subpopulation analysis of NK cells derived from bispecific antibody molecule-amplified PBMCs

[0096] (1) Intracellular molecular labeling Cell monensin induction: Cultured cells 4 × 10 6 The cells (2 ml) were placed in a 6-well plate and induced with 10 μl of monensin (0.5 μg / μl) at 37° C. in a 5% CO 2 incubator for 4 hours. (2) Preparation of single-cell suspension: 9.0 × 10 cells cultured from surface molecule-labeled cells 6After the induction of intracellular molecular labeling, the cells were washed twice with 5 ml of 1x PBS and finally resuspended in 180 μl of 1x PBS. (3) Closure: 90 μl of mouse serum was added to the surface molecule-labeled cells and mixed uniformly. 20 μl of mouse serum was added to the intracellular molecule-labeled cells and mixed uniformly. The cells were then allowed to stand at room temperature for 15 to 30 minutes. (4) Antibody labeling: Surface molecule-labeled cells after closure were dispensed into 9 flow tubes at 0.09 ml / tube each. When multiple batches of cells were detected simultaneously, the cells in tubes 1-8 could be mixed with multiple batches of cells in equal amounts for labeling. The amount of cells used in each tube was 0.8-1 × 10 6 1 x 10 cells, sample tube 2 is surface molecular labeling, and the cell usage is 0.8-1 x 10 6 Sample tube 2 is intracellular molecular labeling, and the cell usage is 3-4 × 10 6 The corresponding fluorescently labeled antibody is added, mixed uniformly, and then allowed to stand at 4°C in the dark for 30 minutes (mixing once every 15 minutes). Specific experimental groupings are shown in Table 2.

[0097] [Table 2] (5) Washing: Add 1ml of 1x PBS to each tube of surface molecule-labeled cells, and collect the cells by centrifugation at 400g for 8 minutes at 4℃. Wash twice with 1ml of 1x PBS. Finally, add 200ul of PBS to each tube to resuspend the labeled cells, add 5μl of DAPI (50μg / ml, 40x) to the experimental group, transfer to a tube and detect on the monitor. (6) Detection: The flow cytometer is calibrated and adjusted according to the instrument specifications. The blank control tube sample is used to adjust the forward scatter and side scatter voltages. The single-target control sample is used to adjust the fluorescence compensation of each channel. After drawing the cell gate during detection, 1 × 104 Collect cells.

[0098] Specific experimental results are shown in Figure 7-D. Subpopulation analysis was performed on the expanded cells. After culture expansion of PBMC cells with anti-CD16a-FCγ4-IL21, the proportion of NK cells reached 61%, the proportion of NKT cells was about 10%, and the total CD56-positive cells was about 71%. The proportion of the remaining cell subpopulations in the expanded PBMC cells was low.

[0099] 4.3 Detection of the killing activity of bispecific antibody molecule-amplified NK cells (1) Preparation of target cell (K562) suspension Cell counting: Cells were resuspended in 1640 medium containing 0.5% FBS (the medium used for target cells) and counted to obtain a cell density of 1 × 10 6 / mL, CFSE staining: Add CFSE (working concentration 5 μM) to the cell suspension, immediately mix by blowing with a 1 mL pipette, vortex thoroughly, and incubate in a 37 °C culture tank in the dark for 15 min, remove the vortex and mix once every 5 min, Stop staining: Add 5 times the volume of pre-cooled complete medium (medium used for target cells) at 4℃ to stop staining, and place in ice bath for 5 minutes. Centrifuge at 140g, 4℃, 5 minutes. Cell washing: Resuspend the cells in complete medium (the medium used for target cells) pre-cooled at 4°C, centrifuge at 140g, 4°C, 5 min, and wash twice. Counting: Resuspend and count the cells to obtain a cell density of 2 x 10 5 / mL, Plate: 100 μl of K562 suspension was added to each well of a 96-well round bottom plate, with the final cell number per well being 20,000 cells / well. (2) Preparation and addition of NK cells Prepare appropriate NK cell density. Take E-Plate 16 and place it on the ultra-clean table. 100μl of NK cell suspension was added into the culture plate at different effector target ratios (CD56+:K562) (1:1, 2:1, 4:1, 8:1), and three sets of controls were also set up: target cells with CFSE staining only (to detect the natural death rate of target cells), effector cells only (to prove that effector cells do not contain CFSE non-specific staining), and target cells + Tween-20 (as a positive control for target cell apoptosis). Co-incubate and add NK cells to each well in a pre-designed order. Centrifuge at 120g for 2 minutes at room temperature to allow effective target cells to contact thoroughly. Return to the culture tank at 37°C and incubate for 4 hours.

[0100] After the incubation is completed, 5 μl of PI is added, mixed uniformly, incubated in the dark for 5 min, and detected by the instrument. Results analysis: Percentage killing = [(% cell death of experimental group -% death of target cells) / (100% -% natural death of target cells)] x 100%).

[0101] Specific experimental results are shown in Figure 7E (7-E), which evaluates the cytotoxicity of the amplified cells, showing that the amplified cells can effectively kill K562 cells.

[0102] As described above, the experimental results of this embodiment demonstrate that anti-CD16a-FCγ4-IL21 can activate and amplify the activity of NK cells in vitro, and the expanded NK cells have relatively good cytotoxicity.

[0103] In the present specification, the reference words such as "one embodiment", "some embodiments", "examples", "specific examples", or "some examples" refer to specific features, structures, materials, or characteristics described in the embodiment or example in combination with each other, which are included in at least one embodiment or example of the present invention. In the present specification, the exemplary descriptions of the above terms do not necessarily refer to the same embodiment or example. In addition, specific features, structures, materials, or characteristics described may be combined in an appropriate manner in one or more embodiments or examples. Furthermore, if not in conflict with each other, a person skilled in the art may combine different embodiments or examples described herein and features of different embodiments or examples.

[0104] Although the embodiments of the present invention have been presented and described, the above embodiments are illustrative and cannot be understood as limiting the present invention, and it will be understood by those skilled in the art that various changes, modifications, substitutions and variations of the above embodiments are possible within the scope of the present invention.

[0105] This application claims priority to a Chinese patent application with application number 202111564703.3, proposed to the China Patent Office on December 20, 2021, the entire contents of which are incorporated herein by reference.

Claims

1. A recombinant antibody comprising: An IL-21 molecule, a CD16a single chain antibody and an Fc region, the N-terminus of the Fc region being connected to the C-terminus of the single chain antibody, the CD16a single chain antibody comprising a CD16a antibody comprising a heavy chain variable region and a light chain variable region; A recombinant antibody, wherein the C-terminus of the FC is connected to the N-terminus of the IL21 molecule.

2. The antibody further comprises a connecting peptide 1, wherein the N-terminus of the connecting peptide 1 is connected to the C-terminus of the heavy chain variable region of the CD16a single chain antibody, and the C-terminus of the connecting peptide 1 is connected to the N-terminus of the light chain variable region of the CD16a single chain antibody; Optionally, the connecting peptide 1 has the amino acid sequence shown in SEQ ID NO:

1. The recombinant antibody of claim 1.

3. Further comprising a connecting peptide 2, the N-terminus of the connecting peptide 2 being connected to the C-terminus of the IL-21 molecule, and the C-terminus of the connecting peptide 2 being connected to the N-terminus of the Fc region; Optionally, the connecting peptide 2 has the amino acid sequence shown in SEQ ID NO:

2. The recombinant antibody of claim 1 .

4. 4. The recombinant antibody of claim 3, wherein at least a portion of the Fc region is derived from at least one of a mouse-origin antibody, a human-origin antibody, a primate-origin antibody or a variant thereof.

5. The recombinant antibody according to claim 3 or 4, characterized in that at least a portion of the Fc region is derived from a human source IgG or a variant thereof.

6. The recombinant antibody according to any one of claims 3 to 5, characterized in that at least a portion of the Fc region is derived from human source Fcγ4 or a variant thereof.

7. The recombinant antibody according to any one of claims 3 to 6, characterized in that the Fc region has the amino acid sequence shown in SEQ ID NO:

3.

8. The recombinant antibody according to any one of claims 1 to 7, characterized in that it has the amino acid sequence shown in SEQ ID NO:

4.

9. A nucleic acid encoding a recombinant antibody according to any one of claims 1 to 8.

10. The nucleic acid according to claim 9, characterized in that it has the nucleotide sequence shown in SEQ ID NO:

5.

11. An expression vector, characterized in that it carries the nucleic acid molecule according to claim 9 or 10.

12. A recombinant cell, characterized in that it carries a nucleic acid molecule according to claim 9 or 10, an expression vector according to claim 11 or a recombinant antibody according to any one of claims 1 to 8.

13. A composition comprising a recombinant antibody according to any one of claims 1 to 8, a nucleic acid molecule according to claim 9 or 10, an expression vector according to claim 11 or a recombinant cell according to claim 12.

14. Use of a recombinant antibody according to any one of claims 1 to 8, a nucleic acid molecule according to claim 9 or 10, an expression vector according to claim 11, a recombinant cell according to claim 12 or a composition according to claim 13 in the manufacture of a medicament for treating or preventing a tumor or a viral infection.

15. 15. The use according to claim 14, characterized in that the tumor comprises at least one of rectal cancer, lung cancer, breast cancer, liver cancer, gastric cancer, skin cancer, renal cancer, pancreatic cancer and ovarian cancer, and the viral infection comprises at least one of HPV, HBV, influenza virus and coronavirus.

16. Use of the recombinant antibody according to any one of claims 1 to 8, the nucleic acid molecule according to claim 9 or 10, the expression vector according to claim 11, or the recombinant cell according to claim 12 in the culture and expansion of NK cells.

17. The use according to claim 16, characterized in that the NK cells are derived from peripheral blood or obtained by stem cell derivation.

18. The use according to claim 16, characterized in that the NK cells comprise at least one of human peripheral blood mononuclear cell-derived NK cells, human umbilical cord blood stem cell-derived NK cells, human embryonic stem cell-derived NK cells, and human iPSC-derived NK cells.

19. A drug comprising a recombinant antibody according to any one of claims 1 to 8, a nucleic acid molecule according to claim 9 or 10, an expression vector according to claim 11, a recombinant cell according to claim 12 or a composition according to claim 13, said drug being used for treating or preventing a tumor or a viral infection.

20. The drug of claim 19, characterized in that the tumor comprises at least one of rectal cancer, lung cancer, breast cancer, liver cancer, gastric cancer, skin cancer, renal cancer, pancreatic cancer and ovarian cancer, and the viral infection comprises at least one of HPV, HBV, influenza virus and coronavirus.

21. A reagent kit comprising the recombinant antibody according to any one of claims 1 to 8.

22. The reagent kit according to claim 21, characterized in that the reagent kit is used for detecting CD16a and / or IL-21R.

23. Use of a recombinant antibody according to any one of claims 1 to 8, a nucleic acid molecule according to claim 9 or 10, an expression vector according to claim 11, a recombinant cell according to claim 12, a composition according to claim 13 or a drug according to any one of claims 19 to 20 in the treatment or prevention of tumors or viral infections.

24. 24. The use according to claim 23, characterized in that the tumor comprises at least one of rectal cancer, lung cancer, breast cancer, liver cancer, gastric cancer, skin cancer, renal cancer, pancreatic cancer and ovarian cancer, and the viral infection comprises at least one of HPV, HBV, influenza virus and coronavirus.

25. Subjects were asked, 1) A recombinant antibody according to any one of claims 1 to 8, 2) A nucleic acid molecule according to claim 9 or 10, 3) The expression vector according to claim 11. 4) The recombinant cell according to claim 12. 5) The composition according to claim 13, or 6) A method for treating or preventing a tumor or a viral infection, comprising the step of administering at least one of the drugs according to any one of claims 19 to 20.

26. 26. The method of claim 25, wherein the tumor comprises at least one of colon cancer, lung cancer, breast cancer, liver cancer, gastric cancer, skin cancer, renal cancer, pancreatic cancer, and ovarian cancer, and the viral infection comprises at least one of HPV, HBV, influenza virus, and coronavirus.

Citation Information

Patent Citations

  • Enhanced NK cell with strong immune regulation and strong killing capacity on tumor cells and virus infected cells, preparation method and kit thereof

    CN111394310A

  • Culturing method involving activity and proliferation of lymphocyte

    JP2007297291A

  • Multispecific and multifunctional molecules and uses thereof

    JP2019512272A

  • Single-chain and multi-chain chimeric polypeptides and methods of use thereof

    JP2021534835A